Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
03/2009
03/19/2009US20090076041 Acyclic nucleoside derivatives
03/19/2009US20090076040 Deuterium-enriched valganciclovir
03/19/2009US20090076039 Deuterium-enriched valacyclovir
03/19/2009US20090076038 Deuterium-enriched entecavir
03/19/2009US20090076012 Modulation of pathogenicity
03/19/2009US20090075995 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
03/19/2009US20090075991 Deuterium-enriched efavirenz
03/19/2009US20090075981 INHIBITORS OF p38
03/19/2009US20090075969 Deuterium-enriched doripenem
03/19/2009US20090075967 Deuterium-enriched ceftriaxone
03/19/2009US20090075966 Deuterium-enriched tazobactam
03/19/2009US20090075965 Deuterium-enriched amoxicilin
03/19/2009US20090075942 Deuterium-enriched fosamprenavir
03/19/2009US20090075939 Novel HIV reverse transcriptase inhibitors
03/19/2009US20090075936 Proteasome inhibitors and methods of using the same
03/19/2009US20090075929 Ig20 splice variants therapeutics for cancer
03/19/2009US20090075928 G-QUARTET OLIGONUCLEOTIDES THAT TARGET HYPOXIA-INDUCIBLE FACTOR 1-a (HIF1a )
03/19/2009US20090075917 Deuterium-enriched telithromycin
03/19/2009US20090075885 Antitumor effect of mutant bik
03/19/2009US20090075874 Methods for construction and screening of libraries of chemokine variants
03/19/2009US20090075870 Deuterium-enriched caspofungin
03/19/2009US20090075839 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigents and uses thereof
03/19/2009US20090075327 Methods for improving secondary metabolite production in fungi
03/19/2009US20090074893 Antiviral peptides
03/19/2009US20090074890 Substituted Triazoles as Sodium Channel Blockers
03/19/2009US20090074875 Nanoparticulate compositions having lysozyme as a surface stabilizer
03/19/2009US20090074859 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
03/19/2009US20090074858 Sustained-release formulation
03/19/2009US20090074853 Vaccines with enhanced immune response and methods for their preparation
03/19/2009US20090074810 Modified Adenovirus Hexon Protein and Uses Thereof
03/19/2009US20090074808 Secreted Streptococcus Pneumoniae Proteins
03/19/2009US20090074807 Moraxella (branhamella) catarrhalis antigens
03/19/2009US20090074806 Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics
03/19/2009US20090074805 Yeast-based Therapeutic for Chronic Hepatitis C Infection
03/19/2009US20090074804 Vero cell-based influenza virus strains and vaccines
03/19/2009US20090074802 Immunomodulating oligopeptides
03/19/2009US20090074798 System and method for the production of recombinant glycosylated proteins in a prokaryotic host
03/19/2009US20090074792 Compositions containing full-length L1R nucleic acid and endoplasmic reticulum-targeting sequence, and methods of use
03/19/2009US20090074788 Antibody Against Periostin, and a Pharmaceutical Composition comprising it for Preventing or Treating a Disease in which Periostin is Involved
03/19/2009US20090074787 Anti-CTLA4 Antibody and Indolinone Combination Therapy for Treatment of Cancer
03/19/2009US20090074781 Dengue virus peptide vaccine and methods of preparing and using the same
03/19/2009US20090074777 Wnt proteins and detection and treatment of cancer
03/19/2009US20090074773 Cancer vaccine
03/19/2009US20090074772 Anti-CD70 Antibody and Its Use for the Treatment of Cancer and Immune Disorders
03/19/2009US20090074768 Activin-actriia antagonists and uses for treating or preventing breast cancer
03/19/2009US20090074762 Therapeutic use of anti-tweak receptor antibodies
03/19/2009US20090074755 Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
03/19/2009US20090074726 Mva expressing modified hiv envelope, gag, and pol genes
03/19/2009US20090074721 Methods for treating viral infection with oral or injectibel drug solution
03/19/2009US20090074716 method for treating influenza virus infection
03/19/2009US20090074715 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[3-(4-morpholinylcarbonyl)-2-pyridinyl]-, 1,1-dimethylethyl ester; 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[2-(4-morpholinylcarbonyl)phenyl]-, 1,1-dimethylethyl ester
03/19/2009US20090074688 Antimicrobial Lotion Compositions
03/19/2009US20090074666 Peptide vaccine for influenza virus
03/19/2009CA2731204A1 Use of a peptide as a therapeutic agent
03/19/2009CA2704726A1 Use of a defensin peptide as a therapeutic agent
03/19/2009CA2699550A1 Method of inhibiting clostridium difficile by administration of oritavancin
03/19/2009CA2699468A1 Composition for preventing virus infection comprising poly-gamma-glutamic acid
03/19/2009CA2699222A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699215A1 (d-leu7 ) -histrelin as a therapeutic agent
03/19/2009CA2699167A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699026A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699020A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699012A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699010A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699008A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699006A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698992A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698985A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698984A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698981A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698980A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698978A1 Use of human neuropeptide af as a therapeutic agent
03/19/2009CA2698977A1 Use of c-type natriuretic peptide, alone or incombination with neuropeptide af, as a therapeutic agent
03/19/2009CA2698976A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698974A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698971A1 Use of urodilatin as a therapeutic agent
03/19/2009CA2698966A1 Use of fertirelin and delta-endorphin as therapeutic agents
03/19/2009CA2698963A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698912A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698855A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698852A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698833A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698831A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698828A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698825A1 Deuterated 4 -oxoquinoline derivatives for the treatment of hiv infection
03/19/2009CA2698824A1 Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine
03/19/2009CA2698822A1 Minigastrin as a therapeutic agent
03/19/2009CA2698821A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698786A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698783A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698778A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698770A1 Use of secretin and optionally urodilatin as a therapeutic agents
03/19/2009CA2698759A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698754A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698748A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698745A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698693A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698691A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698682A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698666A1 Use of a peptide as a therapeutic agent
1 ... 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 ... 1798